Outlook Therapeutics, Inc.
OTLKNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $13.23M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.16$2.54
- Volume (live)
- -
- Avg. volume (3M)
- 4.32M
Outlook Therapeutics (OTLK) Stock Price & Financial Analysis
Outlook Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.49 - $0.53 |
|---|---|
| 52-Week High | $2.54 |
| 52-Week Low | $0.16 |
| Open | $0.51 |
| Volume (last close) | 2.53M |
| Average Volume (3M) | 4.32M |
| Revenue (TTM) | -1.16M |
|---|---|
| Net Income (TTM) | -61.12M |
| Free Cash Flow (TTM) | -57.13M |
| EPS (TTM) | −$1.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 13.23M |
|---|---|
| Shares Outstanding | 25.48M |
| Price to Book (P/B) | -1.27 |
| EV/EBITDA | -0.34 |
| 50-Day MA | $0.65 |
|---|---|
| 200-Day MA | $0.66 |
| 1-Year Change | −56.65% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Outlook Therapeutics at a Glance
As of the Oct 26, 2026 close, Outlook Therapeutics (OTLK) has a market capitalization of $13.23M. Over the trailing twelve months it lost $61.12M on revenue of −$1.16M and burned $57.13M of free cash flow. Revenue fell 177.3% year over year.
As of its latest reported balance sheet, it holds $11.24M in cash and securities against $18.37M of debt, a net debt position of $7.13M.
Outlook Therapeutics does not currently pay a dividend.
The share price is down 56.7% over the past year. At $0.51 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $0.16 to $2.54, below its 200-day moving average of $0.66.
Based on 1 professional analyst rating from the past 90 days, the consensus is Hold.
Frequently Asked Questions About Outlook Therapeutics
What is the current stock price for OTLK?
As of the Oct 26, 2026 close, OTLK stock trades at $0.51. The 52-week range is $0.16–$2.54, with a day range of $0.49–$0.53.
What is the P/E ratio for OTLK?
The P/E ratio (Price-to-Earnings) for OTLK is shown in the Key Statistics section. This valuation metric helps compare Outlook Therapeutics, Inc. to industry peers.
Does OTLK pay dividends?
Outlook Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for OTLK?
Based on ratings from 1 professional analyst over the last 90 days, the consensus for OTLK is Hold.
What is the market cap of OTLK?
As of the Oct 26, 2026 close, Outlook Therapeutics's market capitalization is $13.1M, classifying it as a micro-cap company. Outlook Therapeutics operates in the Healthcare sector within the Biotechnology industry.